Modern clinical research: How rapid learning health care and cohort multiple randomised clinical trials complement traditional evidence based medicine

Acta Oncologica

Volumn 54, Issue 9, 2015, Pages 1289-1300

  Lambin, Philippe ^a   Zindler, Jaap ^a   Vanneste, Ben ^a   Van De Voorde, Lien ^a   Jacobs, Maria ^a   Eekers, Daniëlle ^a   Peerlings, Jurgen ^a   Reymen, Bart ^a   Larue, Ruben T H M ^a   Deist, Timo M ^a   De Jong, Evelyn E C ^a   Even, Aniek J G ^a   Berlanga, Adriana J ^a   Roelofs, Erik ^a   Cheng, Qing ^a   Carvalho, Sara ^a   Leijenaar, Ralph T H ^a   Zegers, Catharina M L ^a   Van Limbergen, Evert ^a   Berbee, Maaike ^a   Van Elmpt, Wouter ^a   Oberije, Cary ^a   Houben, Ruud ^a   Dekker, Andre ^a   Boersma, Liesbeth ^a   Verhaegen, Frank ^a   Bosmans, Geert ^a   Hoebers, Frank ^a   Smits, Kim ^a   Walsh, Sean ^a   more..

^a MAASTRICHT UNIVERSITY   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ALTERNATIVE MEDICINE; ARTICLE; CANCER PATIENT; CANCER RADIOTHERAPY; CLINICAL RESEARCH; COHORT ANALYSIS; EVIDENCE BASED MEDICINE; HEALTH CARE; HUMAN; OUTCOME ASSESSMENT; PATIENT CARE; PATIENT DECISION MAKING; PATIENT PREFERENCE; PRIORITY JOURNAL; PROTON THERAPY; RANDOMIZED CONTROLLED TRIAL (TOPIC); RAPID LEARNING HEALTH CARE; NEOPLASMS; PERSONALIZED MEDICINE; PROCEDURES;

EVIDENCE-BASED MEDICINE; HUMANS; NEOPLASMS; PRECISION MEDICINE; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 84955707370     PISSN: 0284186X     EISSN: 1651226X     Source Type: Journal    
DOI: 10.3109/0284186X.2015.1062136     Document Type: Article

References (58)

1. Lambin P, Petit SF, Aerts HJ, van Elmpt WJ, Oberije CJ, Starmans MH, et al. The ESTRO Breur Lecture 2009. From population to voxel-based radiotherapy: exploiting intra-tumour and intra-organ heterogeneity for advanced treatment of non-small cell lung cancer. Radiother Oncol 2010; 96: 145-52.
2. Koboldt DC, Fulton RS, McLellan MD. Comprehensive molecular portraits of human breast tumours. Nature 2012; 490: 61-70.
3. Seigneuric R, Starmans MH, Fung G, Krishnapuram B, Nuyten DS, van Erk A, et al. Impact of supervised gene signatures of early hypoxia on patient survival. Radiother Oncol 2007; 83: 374-82.
4. Starmans MH, Chu KC, Haider S, Nguyen F, Seigneuric R, Magagnin MG, et al. The prognostic value of temporal in vitro and in vivo derived hypoxia gene-expression signatures in breast cancer. Radiother Oncol 2012; 102: 436-43.
5. Starmans MH, Fung G, Steck H, Wouters BG, Lambin P. A simple but highly effective approach to evaluate the prognostic performance of gene expression signatures. PLoS One 2011; 6: e28320.
6. Starmans MH, Lieuwes NG, Span PN, Haider S, Dubois L, Nguyen F, et al. Independent and functional validation of a multi-tumour-type proliferation signature. Br J Cancer 2012; 107: 508-515.
7. Starmans MH, Zips D, Wouters BG, Baumann M, Lambin P. The use of a comprehensive tumour xenograft dataset to validate gene signatures relevant for radiation response. Radiother Oncol 2009; 92: 417-22.
8. Voets AM, Oberije C, Struijk RB, Reymen B, De Ruyck K, Thierens H, et al. No association between TGF-beta1 polymorphisms and radiation-induced lung toxicity in a European cohort of lung cancer patients. Radiother Oncol 2012; 105: 296-8.
9. Movsas B, Moughan J, Owen J, Coia LR, Zelefsky MJ, Hanks G, et al. Who enrolls onto clinical oncology trials? A radiation patterns of care study analysis. Int J Radiat Oncol Biol Phys 2007; 68: 1145-50.
10. Grand MM, OBrien PC. Obstacles to participation in randomised cancer clinical trials: a systematic review of the literature. J Med Imaging Radiat Oncol 2012; 56: 31-9.
11. Murthy VH, Krumholz HM, Gross CP. Participation in cancer clinical trials: race-, sex-, and age-based disparities. JAMA 2004; 291: 2720-6.
12. Sinha G. United Kingdom becomes the cancer clinical trials recruitment capital of the world. J Natl Cancer Inst 2007; 99: 420-2.
13. Bastian H, Glasziou P, Chalmers I. Seventy-five trials and eleven systematic reviews a day: how will we ever keep up? PLoS Med 2010; 7: e1000326.
14. Abernethy AP, Etheredge LM, Ganz PA, Wallace P, German RR, Neti C, et al. Rapid-learning system for cancer care. J Clin Oncol 2010; 28: 4268-74.
15. Relton C, Torgerson D, OCathain A, Nicholl J. Rethinking pragmatic randomised controlled trials: introducing the "cohort multiple randomised controlled trial" design. BMJ. 2010; 19: c1066.
16. Dehing-Oberije C, Yu S, De Ruysscher D, Meersschout S, Van Beek K, Lievens Y, et al. Development and external validation of prognostic model for 2-year survival of non-small-cell lung cancer patients treated with chemoradiotherapy. Int J Radiat Oncol Biol Phys 2009; 74: 355-62.
17. Egelmeer AG, Velazquez ER, de Jong JM, Oberije C, Geussens Y, Nuyts S, et al. Development and validation of a nomogram for prediction of survival and local control in laryngeal carcinoma patients treated with radiotherapy alone: a cohort study based on 994 patients. Radiother Oncol 2011; 100: 108-15.
18. Jimenez MF, van Baardwijk A, Aerts HJ, De Ruysscher D, Novoa NM, Varela G, et al. Effectiveness of surgery and individualized high-dose hyperfractionated accelerated radiotherapy on survival in clinical stage I non-small cell lung cancer. A propensity score matched analysis. Radiother Oncol 2010; 97: 413-7.
19. Roelofs E, Engelsman M, Rasch C, Persoon L, Qamhiyeh S, de Ruysscher D, et al. Results of a multicentric in silico clinical trial (ROCOCO): comparing radiotherapy with photons and protons for non-small cell lung cancer. J Thorac Oncol 2012; 7: 165-76.
20. Lambin P, Rios-Velazquez E, Leijenaar R, Carvalho S, van Stiphout RG, Granton P, et al. Radiomics: extracting more information from medical images using advanced feature analysis. Eur J Cancer 2012; 48: 441-6.
21. Berry D. Bayesian clinical trials. Nat Rev Drug Disc 2006; 5: 27-36.
22. Mehta C, Pocock S. Adaptive increase in sample size when interim results are promising: A practical guide with examples. Stat Med 2011; 10: 3267-84.
23. Thomas C, Baker S, Baker M. Overhauling clinical trials. Nat Biotech 2007; 25 (3): 287-92.
24. Skripcak T, Belka C, Bosch W, Brink C, Brunner T, Budach V, et al. Creating a data exchange strategy for radiotherapy research: Towards federated databases and anonymised public datasets. Radiother Oncol 2014; 113: 303-9.
25. Deasy JO, Bentzen SM, Jackson A, Ten Haken RK, Yorke ED, Constine LS, et al. Improving Normal Tissue Complication Probability Models: The Need to Adopt a "Data-Pooling" Culture. Int J Radiat Oncol Biol Phys 2010; 76: S151-S4.
26. Meldolesi E, van Soest J, Dinapoli N, Dekker A, Damiani A, Gambacorta M, et al. An umbrella protocol for standardized data collection (SDC) in rectal cancer: a prospective uniform naming and procedure convention to support personalized medicine. Radiother Oncol 2014; 112: 59-62.
27. Steyerberg EW, Vickers AJ, Cook NR, Gerds T, Gonen M, Obuchowski N, et al. Assessing the performance of prediction models: a framework for traditional and novel measures. Epidemiology 2010; 21: 128-38.
28. Valentini V, van Stiphout R, Lammering G, Gambacorta M, Barba M, Bebenek M, et al. Nomograms for predicting local recurrence, distant metastases, and overall survival for patients with locally advanced rectal cancer on the basis of European randomized clinical trials. J Clin Oncol 2011; 29: 3163-72.
29. De Ruysscher D, Dehing C, Yu S, Wanders R, Ollers M, Dingemans A, et al. Dyspnea evolution after high-dose radiotherapy in patients with non-small cell lung cancer. Radiother Oncol 2009; 91: 353-9.
30. De Ruysscher D, Houben A, Aerts H, Dehing C, Wanders R, Ollers M, et al. Increased (18)F-deoxyglucose uptake in the lung during the first weeks of radiotherapy is correlated with subsequent Radiation-Induced Lung Toxicity (RILT): a prospective pilot study. Radiother Oncol 2009; 91: 415-20.
31. Collins G, Reitsma J, Altman D, Moons K. Transparent reporting of a multivariable prediction model for individual prognosis or diagnosis (TRIPOD): the TRIPOD Statement. Ann Intern Med 2015; 162: 55-63.
32. Dehing-Oberije C, De Ruysscher D, van Baardwijk A, Yu S, Rao B, Lambin P. The importance of patient characteristics for the prediction of radiation-induced lung toxicity. Radiother Oncol 2009; 91: 421-6.
33. Stacey D, Bennett CL, Barry MJ, Col NF, Eden KB, Holmes-Rovner M, et al. Decision aids for people facing health treatment or screening decisions. Cochrane Database Syst Rev 2011; 10:C D001431.
34. Michalski JM, Gay H, Jackson A, Tucker SL, Deasy JO. Radiation dose volume effects in radiation induced rectal injury. Int J Rad Oncol Biol Phys 2010; 76: S123-S9.
35. Walsh S, van der Putten W. A TCP model for external beam treatment of intermediate-risk prostate cancer. Med Phys 2013; 40: 031709.
36. Dekker A, Vinod S, Holloway L, Oberije C, George A, Goozee G, et al. Rapid learning in practice: A lung cancer survival decision support system in routine patient care data. Radiother Oncol 2014; 113: 47-53.
37. Lambin P, van Stiphout RG, Starmans MH, Rios-Velazquez E, Nalbantov G, Aerts HJ, et al. Predicting outcomes in radiation oncology-multifactorial decision support systems. Nat Rev Clin Oncol 2013; 10: 27-40.
38. Dehing-Oberije C, De Ruysscher D, Petit S, Van Meerbeeck J, Vandecasteele K, De Neve W, et al. Development, external validation and clinical usefulness of a practical prediction model for radiation-induced dysphagia in lung cancer patients. Radiother Oncol 2010; 97: 455-61.
39. Dehing-Oberije C, Aerts H, Yu S, De Ruysscher D, Menheere P, Hilvo M, et al. Development and validation of a prognostic model using blood biomarker information for prediction of survival of non-small-cell lung cancer patients treated with combined chemotherapy and radiation or radiotherapy alone (NCT00181519, NCT00573040, and NCT00572325). Int J Rad Oncol Biol Phys 2011; 81: 360-8.
40. Zindler J, Rodrigues G, Haasbeek C, De Haan P, Meijer O, Slotman B, et al. The clinical utility of prognostic scoring systems in patients with brain metastases treated with radiosurgery. Radiother Oncol 2013; 106: 370-4.
41. Wiggenraad R, Verbeek-de Kanter A, Kal H, Taphoorn M, Vissers T, Struikmans H. Dose-effect relation in stereotactic radiotherapy for brain metastases. A systematic review. Radiother Oncol 2011; 98: 292-7.
42. Yamamoto M, Serizawa T, Shuto T, Akabane A, Higuchi Y, Kawagishi J, et al. Stereotactic radiosurgery for patients with multiple brain metastases (JLGK0901): a multi-institutional prospective observational study. Lancet Oncol 2014; 15: 387-95.
43. Langley R, Stephens R, Nankivell M, Pugh C, Moore B, Navani N, et al. Interim data from the Medical Research Council QUARTZ Trial: does whole brain radiotherapy affect the survival and quality of life of patients with brain metastases from non-small cell lung cancer? Clin Oncol 2013; 25: 23-5.
44. Brewin C, Bradley C. Patient preferences and randomised clinical trials. BMJ 1989; 299: 313-315.
45. Francis T, Korns R, Voight R, Boisen M, Hemphill F, Napier J. Evaluation of the 1954 poliomyelitis vaccine field trial; further studies of results determining the effectiveness of poliomyelitis vaccine (Salk) in preventing paralytic poliomyelitis. J Am Med Assoc 1954; 158: 1266-70.
46. Olschewski M, Scheurlen H. Comprehensive cohort study: an alternative to randomised consent design in a breast preservation trial. Methods Inf Med 1985; 24: 131-4.
47. Zelen M. A new design for randomized clinical trials. N Engl J Med 1979; 300: 1242-5.
48. Holland A, Palaniappan L. Problems With the Collection and Interpretation of Asian-American Health Data: Omission, Aggregation, and Extrapolation. Ann Epidemiol 2012; 22: 397-405.
49. Britton A, McKee M, Black N, McPherson K, Sanderson C, Bain C. Choosing between randomised and non randomised studies: a systematic review. Health Technol Assess 1998; 2: 1-4.
50. Ross S, Grant A, Counsell C, Gillespie W, Russell I, Prescott R. Barriers to participation in randomised controlled trials: a systematic review. J Clin Epidemiol 1999; 52: 1143-56.
51. Firth J. Should you tell patients about beneficial treatments that they cannot have? BMJ 2007; 334: 827.
52. Pieterse A, Henselmans I, de Haes H, Koning C, Geijsen E, Smets E. Shared decision making: prostate cancer patients appraisal of treatment alternatives and oncologists eliciting and responding behavior, an explorative study. Patient Educ Couns 2011; 85 (3).
53. Burbach J, Verkooijen H, Intven M, Kleijnen J, Bosman M, Raaymakers B, et al. RandomizEd Controlled Trial for pre-operAtive dose-escaLation BOOST in locally advanced rectal cancer (RECTAL BOOST study): study protocol for a randomized controlled trial. Trials 2015; 22: 58.
54. Lambin P, Roelofs E, Reymen B, Velazquez E, Buijsen J, Zegers C, et al. Rapid Learning health care in oncology-An approach towards decision support systems enabling customised radiotherapy. Radiother Oncol 2013; 109: 159-64.
55. Aerts HJ, Bussink J, Oyen WJ, van Elmpt W, Folgering AM, Emans D, et al. Identification of residual metabolic-active areas within NSCLC tumours using a pre-radiotherapy FDG-PET-CT scan: a prospective validation. Lung Cancer 2012; 75: 73-6.
56. van Loon J, Janssen MH, Ollers M, Aerts HJ, Dubois L, Hochstenbag M, et al. PET imaging of hypoxia using [18F]HX4: a phase I trial. Eur J Nucl Med Mol Imaging 2010; 37: 1663-8.
57. Stiggelbout AM, Van der Weijden T, De Wit MP, Frosch D, Legare F, Montori VM, et al. Shared decision making: really putting patients at the centre of healthcare. BMJ 2012; 344: e256.
58. Clegg A, Relton C, Young J, Witham M. Improving recruitment of older people to clinical trials: use of the cohort multiple randomised controlled trial design. Age Aging 2015; 44: 547-50.